Trial Profile
Phase Ib allergen challenge trial of R 343 in patients with mild allergic asthma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2012
Price :
$35
*
At a glance
- Drugs R 343 (Primary) ; Fluticasone propionate
- Indications Allergic asthma
- Focus Pharmacodynamics
- Sponsors Pfizer
- 20 May 2012 Results reported at the 108th International Conference of the American Thoracic Society.
- 05 Aug 2011 Results will be presented at an analyst/investor meeting in New York City in October 2011
- 05 Aug 2011 New trial record